share_log

Longeveron Highlights Publication Of Final Data From ELPIS I Trial Of Lomecel-BTM

Benzinga Real-time News ·  Jan 19, 2023 08:33

-- Full results published in European Heart Journal Open --

-- Study met primary safety endpoint --

-- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment --

-- Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial --

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment